Focused On-demand Library for NADH dehydrogenase (ubiquinone) complex I, assembly factor 6

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q330K2

UPID:

NDUF6_HUMAN

Alternative names:

Putative phytoene synthase

Alternative UPACC:

Q330K2; A8MT28; A8MWF0; B4DQ45; Q8N6U6

Background:

NADH dehydrogenase (ubiquinone) complex I, assembly factor 6, also known as Putative phytoene synthase, plays a crucial role in the assembly of mitochondrial NADH:ubiquinone oxidoreductase complex (complex I), particularly at early stages. It is instrumental in the biogenesis of complex I subunit MT-ND1, a key component in mitochondrial function.

Therapeutic significance:

This protein is linked to mitochondrial complex I deficiency, nuclear type 17, and Fanconi renotubular syndrome 5, diseases characterized by mitochondrial dysfunction. Understanding its role could lead to novel therapeutic strategies targeting mitochondrial disorders, offering hope for patients with these challenging conditions.